CoChat
Sign Up
Cited by 110

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer

Yamato, K, Yamada, T, Kizaki, M, Ui-Tei, K, Natori, Y, Fujino, M, Nishihara, T, Ikeda, Y, Nasu, Y, Saigo, K, Yoshinouchi, M·2008·Cancer Gene Therapy
DOI 10.1038/sj.cgt.7701118
Open this paper in CoChat — free account

Abstract

Persistent infection by high-risk types of human papillomaviruses (HPV) is a necessary cause of cervical cancer, with HPV16 the most prevalent, accounting for more than 50% of reported cases. The virus encodes the E6 and E7 oncoproteins, whose expression is essential for maintenance of the malignant phenotype. To select efficacious siRNAs applicable to RNAi therapy for patients with HPV16+ cervical cancer, E6 and E7 siRNAs were designed using siDirect computer software, after which 10 compatible with all HPV16 variants were selected, and then extensively examined for RNAi activity and specificity using HPV16+ and HPV16-cells. Three siRNAs with the highest RNAi activities toward E6 and E7 expression, as well as specific and potent growth suppression of HPV16+ cancer cells as low as 1 nM were chosen. Growth suppression was accompanied by accumulation of p53 and p21(WAF1/CIP1), as well as morphological and cytochemical changes characteristic of cellular senescence. Antitumor activity of one of the selected siRNAs was confirmed by retarded tumor growth of HPV16+ cells in NOD/SCID mice when locally injected in a complex with atelocollagen. Our results demonstrate that these E6 and E7 siRNAs are promising therapeutic agents for treatment of virus-related cancer.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.cgt.7701118

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 50

  1. Bosch FX, de Sanjose S . Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3–13. · DOI
  2. zur Hausen H . Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 690–698. · DOI
  3. Longworth MS, Laimins LA . Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362–372. · DOI
  4. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78: 11451–11460. · DOI · Paper page
  5. Flores ER, Allen-Hoffmann BL, Lee D, Lambert PF . The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000; 74: 6622–6631. · DOI
  6. Bischof O, Nacerddine K, Dejean A . Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol Cell Biol 2005; 25: 1013–1024. · DOI
  7. Venturini F, Braspenning J, Homann M, Gissmann L, Sczakiel G . Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Res 1999; 27: 1585–1592. · DOI
  8. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A, DiPaolo JA . Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci USA 1998; 95: 1189–1194. · DOI
  9. Chen Z, Kamath P, Zhang S, St John L, Adler-Storthz K, Shillitoe EJ . Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther 1996; 3: 18–23.
  10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–498. · DOI · Paper page
  11. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA . Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742–9747. · DOI
  12. Jiang M, Milner J . Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002; 21: 6041–6048. · DOI
  13. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003; 8: 762–768. · DOI · Paper page
  14. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F . siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938–5945. · DOI · Paper page
  15. Hall AH, Alexander KA . RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003; 77: 6066–6069. · DOI
  16. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005; 68: 1311–1319. · DOI
  17. Niu XY, Peng ZL, Duan WQ, Wang H, Wang P . Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006; 16: 743–751. · DOI
  18. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006; 13: 1023–1032. · DOI
  19. Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J et al. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med 2007; 85: 1253–1262. · DOI
  20. Lin X, Ruan X, Anderson MG, McDowell JA, Kroeger PE, Fesik SW et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 2005; 33: 4527–4535. · DOI
  21. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L et al. Widespread siRNA ‘off-target’ transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12: 1179–1187. · DOI
  22. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263–270. · DOI
  23. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I . Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457–462. · DOI
  24. Haley B, Zamore PD . Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol 2004; 11: 599–606. · DOI · Paper page
  25. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004; 32: 936–948. · DOI
  26. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K . siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res 2004; 32: W124–W129. · DOI
  27. Kanda T, Furuno A, Yoshiike K . Human papillomavirus type 16 open reading frame E7 encodes a transforming gene for rat 3Y1 cells. J Virol 1988; 62: 610–613. · DOI · Paper page
  28. Smotkin D, Prokoph H, Wettstein FO . Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 1989; 63: 1441–1447. · DOI
  29. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD . Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115: 199–208. · DOI · Paper page
  30. Khvorova A, Reynolds A, Jayasena SD . Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209–216. · DOI · Paper page
  31. Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett 2000; 156: 159–165. · DOI
  32. Hu X, Pang T, Guo Z, Ponten J, Nister M, Bernard Afink G . Oncogene lineages of human papillomavirus type 16 E6, E7 and E5 in preinvasive and invasive cervical squamous cell carcinoma. J Pathol 2001; 195: 307–311. · DOI
  33. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H et al. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 2001; 94: 711–716. · DOI
  34. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY et al. Human papillomavirus type 16 intratypic variant infection and risk for cervical neoplasia in southern China. J Infect Dis 2002; 186: 696–700. · DOI
  35. Kammer C, Tommasino M, Syrjanen S, Delius H, Hebling U, Warthorst U et al. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br J Cancer 2002; 86: 269–273. · DOI
  36. Tornesello ML, Duraturo ML, Salatiello I, Buonaguro L, Losito S, Botti G et al. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol 2004; 74: 117–126. · DOI
  37. Brown KM, Chu CY, Rana TM . Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol 2005; 12: 469–470. · DOI
  38. Schubert S, Grunweller A, Erdmann VA, Kurreck J . Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol 2005; 348: 883–893. · DOI
  39. Overhoff M, Alken M, Far RK, Lemaitre M, Lebleu B, Sczakiel G et al. Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol 2005; 348: 871–881. · DOI
  40. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR . Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834–839. · DOI
  41. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J et al. Position-specific chemical modification of siRNAs reduces ‘off-target’ transcript silencing. RNA 2006; 12: 1197–1205. · DOI
  42. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173–178. · DOI
  43. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177–12182. · DOI
  44. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002–1007. · DOI
  45. Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW et al. The microRNAs of Caenorhabditis elegans. Genes Dev 2003; 17: 991–1008. · DOI · Paper page
  46. DeFilippis RA, Goodwin EC, Wu L, DiMaio D . Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77: 1551–1563. · DOI
  47. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K et al. Mitogenic signalling and the p16IINK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8: 1291–1297. · DOI · Paper page
  48. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ . HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152–164. · DOI
  49. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006; 119: 1623–1629. · DOI
  50. Palefsky J . Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol 1995; 7: 437–441. · DOI

Cited by

See all 110

Metadata

Authors
Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., & Yoshinouchi, M.
Venue
Cancer Gene Therapy
Publisher
Springer Science and Business Media LLC
Published
2007-12-21
Volume
15
Issue
3
Pages
140-153
ISSN
  • 0929-1903
  • 1476-5500
DOI
10.1038/sj.cgt.7701118
Cited by
110
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. https://app.cochat.ai/papers/10.1038/sj.cgt.7701118
The paper
Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., & Yoshinouchi, M. (2008). New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Therapy. https://doi.org/10.1038/sj.cgt.7701118